{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:11:45Z","timestamp":1787170305325,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA164273"],"award-info":[{"award-number":["R01CA164273"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["K12CA087723"],"award-info":[{"award-number":["K12CA087723"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.lungcan.2026.108945","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T16:25:07Z","timestamp":1769531107000},"page":"108945","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Combination therapy with lorlatinib and mitogen-activated protein kinase pathway inhibition in previously treated ALK- or ROS1-rearranged lung cancer"],"prefix":"10.1016","volume":"213","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2591-2279","authenticated-orcid":false,"given":"Jaime L.","family":"Schneider","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alona","family":"Muzikansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin F.","family":"Gainor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7373-3916","authenticated-orcid":false,"given":"Jessica J.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Symes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice T.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibiayi","family":"Dagogo-Jack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lungcan.2026.108945_b0005","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/s43018-023-00515-0","article-title":"ALK-positive lung cancer: a moving target","volume":"4","author":"Schneider","year":"2023","journal-title":"Nat Cancer."},{"key":"10.1016\/j.lungcan.2026.108945_b0010","doi-asserted-by":"crossref","unstructured":"M.C. Boulanger, J.L. Schneider, J.J. Lin, Advances and future directions in ROS1 fusion-positive lung cancer, Oncologist. (2024), doi:10.1093\/oncolo\/oyae205.","DOI":"10.1093\/oncolo\/oyae205"},{"issue":"15","key":"10.1016\/j.lungcan.2026.108945_b0015","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1158\/1078-0432.CCR-13-0318","article-title":"ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer","volume":"19","author":"Gainor","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.lungcan.2026.108945_b0020","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/jamaoncol.2015.4482","article-title":"Association between younger age and targetable genomic alterations and prognosis in non-small-cell lung cancer","volume":"2","author":"Sacher","year":"2016","journal-title":"JAMA Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2026.108945_b0025","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2011.35.6345","article-title":"ROS1 rearrangements define a unique molecular class of lung cancers","volume":"30","author":"Bergethon","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.lungcan.2026.108945_b0030","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2026.108945_b0035","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa2302299","article-title":"Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer","volume":"390","author":"Drilon","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.lungcan.2026.108945_b0040","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/2159-8290.CD-22-0968","article-title":"NVL-520 is a selective, TRK-sparing, and brain-penetrant inhibitor of ROS1 fusions and secondary resistance mutations","volume":"13","author":"Drilon","year":"2023","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.lungcan.2026.108945_b0045","article-title":"A phase 2 study of lorlatinib in patients with ROS1-rearranged lung cancer with brain-only progression on crizotinib","volume":"3","author":"Schneider","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"issue":"6","key":"10.1016\/j.lungcan.2026.108945_b0050","article-title":"Long-term efficacy and safety of entrectinib in ROS1 fusion-positive NSCLC","volume":"3","author":"Drilon","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"issue":"12","key":"10.1016\/j.lungcan.2026.108945_b0055","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S1470-2045(19)30655-2","article-title":"Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial","volume":"20","author":"Shaw","year":"2019","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2026.108945_b0060","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/annonc\/mdz131","article-title":"Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001","volume":"30","author":"Shaw","year":"2019","journal-title":"Ann. Oncol."},{"issue":"21","key":"10.1016\/j.lungcan.2026.108945_b0065","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.lungcan.2026.108945_b0070","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive Non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.lungcan.2026.108945_b0075","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1634\/theoncologist.2012-0311","article-title":"Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology","volume":"17","author":"Ou","year":"2012","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.lungcan.2026.108945_b0080","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","article-title":"Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol."},{"issue":"16","key":"10.1016\/j.lungcan.2026.108945_b0085","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1200\/JCO.18.02236","article-title":"ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer","volume":"37","author":"Shaw","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2026.108945_b0090","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1158\/2159-8290.CD-16-1123","article-title":"Targeting ALK: precision medicine takes on drug resistance","volume":"7","author":"Lin","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lungcan.2026.108945_b0095","doi-asserted-by":"crossref","unstructured":"M. Zahmatyar, L. Kharaz, N. Abiri Jahromi, A. Jahanian, P. Shokri, S.A. Nejadghaderi, The safety and efficacy of binimetinib for lung cancer: a systematic review. BMC Pulm. Med., 24(1) (2024) 379, doi:10.1186\/s12890-024-03178-4.","DOI":"10.1186\/s12890-024-03178-4"},{"issue":"21","key":"10.1016\/j.lungcan.2026.108945_b0100","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1200\/JCO.23.00774","article-title":"Phase II, open-label study of encorafenib plus binimetinib in patients with BRAF(V600)-mutant metastatic non-small-cell lung cancer","volume":"41","author":"Riely","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2026.108945_b0105","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/s43018-022-00399-6","article-title":"Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer","volume":"3","author":"Shiba-Ishii","year":"2022","journal-title":"Nat Cancer."},{"issue":"9","key":"10.1016\/j.lungcan.2026.108945_b0110","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/nm.3930","article-title":"RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer","volume":"21","author":"Hrustanovic","year":"2015","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2026.108945_b0115","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1158\/1078-0432.CCR-19-1104","article-title":"Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer","volume":"26","author":"Recondo","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.lungcan.2026.108945_b0120","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1158\/1078-0432.CCR-19-3321","article-title":"MAPK pathway alterations correlate with poor survival and drive resistance to therapy in patients with lung cancers driven by ROS1 fusions","volume":"26","author":"Sato","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"7610","key":"10.1016\/j.lungcan.2026.108945_b0125","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nature18621","article-title":"Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases","volume":"535","author":"Chen","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2026.108945_b0130","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/bs.acr.2021.07.002","article-title":"Inhibition of SHP2 as an approach to block RAS-driven cancers","volume":"153","author":"Chou","year":"2022","journal-title":"Adv. Cancer Res."},{"issue":"1","key":"10.1016\/j.lungcan.2026.108945_b0135","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.cell.2020.06.013","article-title":"Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma","volume":"182","author":"Gillette","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.lungcan.2026.108945_b0140","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jtho.2023.08.009","article-title":"Targeting SHP2 signaling in lung cancer","volume":"19","author":"Imbody","year":"2024","journal-title":"J. Thorac. Oncol."},{"issue":"17","key":"10.1016\/j.lungcan.2026.108945_b0145","doi-asserted-by":"crossref","first-page":"7773","DOI":"10.1021\/acs.jmedchem.6b00680","article-title":"Allosteric inhibition of SHP2: identification of a potent, selective, and orally efficacious phosphatase inhibitor","volume":"59","author":"Garcia Fortanet","year":"2016","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.lungcan.2026.108945_b0150","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.apsb.2018.08.009","article-title":"SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade","volume":"9","author":"Zhao","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"issue":"4","key":"10.1016\/j.lungcan.2026.108945_b0155","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nm.4497","article-title":"SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors","volume":"24","author":"Dardaei","year":"2018","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.lungcan.2026.108945_b0160","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1182\/blood.2020008136","article-title":"Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma","volume":"139","author":"Karaca Atabay","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.lungcan.2026.108945_b0165","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1158\/2767-9764.CRC-23-0234","article-title":"SHP2 inhibition with TNO155 increases efficacy and overcomes resistance of ALK inhibitors in neuroblastoma","volume":"3","author":"Valencia-Sama","year":"2023","journal-title":"Cancer Res. Commun."},{"issue":"8","key":"10.1016\/j.lungcan.2026.108945_b0170","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1158\/2159-8290.CD-23-0361","article-title":"SHP2 inhibition sensitizes diverse oncogene-addicted solid tumors to re-treatment with targeted therapy","volume":"13","author":"Drilon","year":"2023","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.lungcan.2026.108945_b0175","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201414","article-title":"SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling","volume":"218","author":"Fedele","year":"2021","journal-title":"J. Exp. Med."},{"issue":"8","key":"10.1016\/j.lungcan.2026.108945_b0180","article-title":"Efficacy and tolerability of ALK\/MET combinations in patients with ALK-rearranged lung cancer with acquired MET amplification: a retrospective analysis","volume":"4","author":"Dagogo-Jack","year":"2023","journal-title":"JTO Clin. Res. Rep."},{"issue":"12","key":"10.1016\/j.lungcan.2026.108945_b0185","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1158\/2159-8290.CD-24-0231","article-title":"NVL-655 is a selective and brain-penetrant inhibitor of diverse ALK-mutant oncoproteins, including lorlatinib-resistant compound mutations","volume":"14","author":"Lin","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lungcan.2026.108945_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.108003","article-title":"Alectinib combined with cobimetinib in ALK-rearranged lung cancer: a phase IB study","volume":"199","author":"Dagogo-Jack","year":"2025","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2026.108945_b0195","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.21037\/tlcr-20-189","article-title":"Future perspectives from lung cancer pre-clinical models: new treatments are coming?","volume":"9","author":"Bersani","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"issue":"10","key":"10.1016\/j.lungcan.2026.108945_b0200","article-title":"Lung cancer organoids as avatars of patients with lung cancer in the prediction of therapeutic response","volume":"4","author":"Rosell","year":"2023","journal-title":"JTO Clin. Res. Rep."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226000395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226000395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T18:05:32Z","timestamp":1774029932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226000395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":40,"alternative-id":["S0169500226000395"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.108945","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination therapy with lorlatinib and mitogen-activated protein kinase pathway inhibition in previously treated ALK- or ROS1-rearranged lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.108945","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108945"}}